CELU - Celularity Inc logo

Celularity Inc

CELU

Celularity Inc. develops off-the-shelf placental-derived cell therapies targeting aging-related and degenerative diseases. Its products include therapies for Crohn's disease, osteoarthritis, and various surgical and wound care solutions, alongside bio banking services.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$15today

Score Overview

1 Year
Score
Net Growth22.53%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-34.70%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.6
Net Growth28.96%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-18.73%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score
Net Growth66.43%
Net Trend71%
Net Income Consistency
Rev Growth-18.01%
Rev Trend43%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Celularity Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CELU does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.05โ€”
1 Year2025-10-22
$ 2.01-47.66%
5 Years2021-10-22
$ 68.90-98.48%
All Time2019-08-08
$ 98.00-98.93%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 17M-$ 71M$ 368K
2025$ 26M-$ 91M$ 6M
2024$ 54M-$ 57M$ 738K
2023$ 22M-$ 196M
2022$ 17M$ 14M$ 13M
2021$ 21M-$ 100M$ 37M
2020$ 14M-$ 208M$ 54M
IPO2019$ 21M-$ 211M$ 28M
CELU - Celularity Inc logo

Celularity Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 14M to $ 26M and net income went from -$ 208M to -$ 91M. Revenue increased in 2 of those 5 years; net income in 3.

Celularity Inc currently holds a 5-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.

Membership

Explore CELU with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies